scholarly journals The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis

2019 ◽  
Vol 12 ◽  
pp. 175628641985918 ◽  
Author(s):  
Daniel Merlo ◽  
David Darby ◽  
Tomas Kalincik ◽  
Helmut Butzkueven ◽  
Anneke van der Walt
Keyword(s):  
Multiple Sclerosis ◽  
Screening Tool ◽  
Practice Effects ◽  
Cognitive Test ◽  
Cognitive Screening ◽  
Cognitive Changes ◽  
Discriminative Ability ◽  
Monitoring Tools ◽  
Home Based ◽  
Home Testing

Background: Multiple sclerosis (MS) cognitive tests are resource intensive and limited by practice effects that prevent frequent retesting. Brief, reliable and valid monitoring tools are urgently needed to detect subtle, subclinical cognitive changes in people with MS. Cognitive monitoring over time could contribute to a new definition of disease progression, supplementing routine clinical monitoring. Methods: MSReactor is a web-based battery that measures psychomotor (processing) speed, visual attention and working memory, using simple reaction time tasks. Clinic-based tasks were completed at baseline and 6 monthly with home testing 1–3 monthly. Acceptability, quality of life, depression and anxiety surveys were completed. We studied its correlation with the Symbol Digit Modalities Test, practice effects, test–retest reliability and the discriminative ability of MSReactor. Results: A total of 450 people with MS were recruited over 18 months, with 81% opting to complete home-based testing. Most participants (96%) would be happy (or neutral) to repeat the tasks again and just four reported the tasks made them ‘very anxious’. Persistence of home testing was high and practice effects stabilized within three tests. MSReactor tasks correlated with Symbol Digit Modalities Test scores and participants with MS performed slower than healthy controls. Conclusion: MSReactor is a scalable and reliable cognitive screening tool that can be used in the clinic and remotely. MSReactor task performance correlated with another highly validated cognitive test, was sensitive to MS and baseline predictors of cognitive performance were identified.

Translation and adaption of short version of IQCODE into Hausa and its psychometric evaluation among outpatients older adults

2021 ◽  
Vol ahead-of-print (ahead-of-print) ◽  
Author(s):  
Tolulope Adeniji ◽  
Adetoyeje Y. Oyeyemi
Keyword(s):  
Older Adults ◽  
Older Adult ◽  
Internal Consistency ◽  
Screening Tool ◽  
Receiver Operating Curve ◽  
Cognitive Screening ◽  
Cronbach’S Alpha ◽  
Cognitive Changes ◽  
Content Type ◽  
Cronbach's Alpha

Purpose This study aims at translating and adapting a common and widely used proxy rated cognitive screening tool – Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) into Hausa language and also to evaluate the instrument’s psychometric properties. Design/methodology/approach IQCODE was translated and adapted using a qualitative process involving experts and the adapted version was then evaluated against a gold standard (Diagnostic and Statistical Manual of Mental Disorder V criteria for neurocognitive disorders) with older adults subjects (N = 100), while its reliability (internal consistency) was also evaluated. Descriptive statistics of mean and frequencies, and inferential statistic of receiver operating curve analysis and Cronbach’s alpha coefficient were used for data analysis at an alpha level set at 0.05. Findings The Hausa IQCODE has a sensitivity value of 73.3%, specificity value of 71.8% and optimal cut-off values of between 3.2 and 3.3. For his adapted instrument the area under the Curve (AUC) curve is 0.79 (95% CI: 0.663–0.919; std. err: 0.066; P = 0.000), and Cronbach’s alpha value of 0.819 was obtained indicating that the adapted instrument has good internal consistency. Research limitations/implications The adapted IQCODE is a valid and reliable proxy based cognitive screening tool for the older adult Hausa speakers in Maiduguri. However, clinician and researcher might want to consider different optimal cut-off points when using this tool to screen or to monitor cognitive changes among older adults. Originality/value This research paper translated and adapted Hausa IQCODE into Hausa language. And it gives information on the validity and reliability of the adapted tool alongside with new optimal cut-off for cognitive screening by proxy among older adult patients in Nigeria.

The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test–retest intervals

2003 ◽  
Vol 9 (3) ◽  
pp. 419-428 ◽  
Author(s):  
ALEXANDER COLLIE ◽  
PAUL MARUFF ◽  
DAVID G. DARBY ◽  
MICHAEL McSTEPHEN
Keyword(s):  
Test Performance ◽  
Neuropsychological Tests ◽  
Test Battery ◽  
Practice Effects ◽  
Cognitive Test ◽  
Drug Induced ◽  
Cognitive Changes ◽  
Before And After ◽  
Neurologically Normal ◽  
Cognitive Test Performance

Performance on many cognitive and neuropsychological tests may be improved by prior exposure to testing stimuli and procedures. These beneficial practice effects can have a significant impact on test performance when conventional neuropsychological tests are administered at test–retest intervals of weeks, months or years. Many recent investigations have sought to determine changes in cognitive function over periods of minutes or hours (e.g., before and after anesthesia) using computerized tests. However, the effects of practice at such brief test–retest intervals has not been reported. The current study sought to determine the magnitude of practice effects in a group of 113 individuals assessed with an automated cognitive test battery on 4 occasions in 1 day. Practice effects were evident both between and within assessments, and also within individual tests. However, these effects occurred mostly between the 1st and 2nd administration of the test battery, with smaller, nonsignificant improvements observed between the 2nd, 3rd, and 4th administrations. On the basis of these results, methodological and statistical strategies that may aid in the differentiation of practice effects from drug-induced cognitive changes are proposed. (JINS, 2003, 9, 419–428.)

Validation of cognitive screening tool to predict fitness-to-drive in individuals with multiple sclerosis

Physiotherapy ◽  
2015 ◽  
Vol 101 ◽  
pp. e45
Author(s):  
H. Devos ◽  
A. Cornelison ◽  
E. De La Cruz ◽  
T. Harris ◽  
K. Phillips ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Screening Tool ◽  
Cognitive Screening ◽  
Fitness To Drive

scholarly journals Recommendations for cognitive screening and management in multiple sclerosis care

2018 ◽  
Vol 24 (13) ◽  
pp. 1665-1680 ◽  
Author(s):  
Rosalind Kalb ◽  
Meghan Beier ◽  
Ralph HB Benedict ◽  
Leigh Charvet ◽  
Kathleen Costello ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Treatment Strategies ◽  
Optimal Strategies ◽  
Current Evidence ◽  
Cognitive Screening ◽  
Optimal Care ◽  
Cognitive Changes ◽  
Adults And Children ◽  
The Individual

Purpose: To promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address barriers to optimal management. Methods: The National MS Society (“Society”) convened experts in cognitive dysfunction (clinicians, researchers, and lay people with MS) to review the published literature, reach consensus on optimal strategies for screening, monitoring, and treating cognitive changes, and propose strategies to address barriers to optimal care. Recommendations: Based on current evidence, the Society makes the following recommendations, endorsed by the Consortium of Multiple Sclerosis Centers and the International Multiple Sclerosis Cognition Society: Increased professional and patient awareness/education about the prevalence, impact, and appropriate management of cognitive symptoms. For adults and children (8+ years of age) with clinical or magnetic resonance imaging (MRI) evidence of neurologic damage consistent with MS: As a minimum, early baseline screening with the Symbol Digit Modalities Test (SDMT) or similarly validated test, when the patient is clinically stable; Annual re-assessment with the same instrument, or more often as needed to (1) detect acute disease activity; (2) assess for treatment effects (e.g. starting/changing a disease-modifying therapy) or for relapse recovery; (3) evaluate progression of cognitive impairment; and/or (4) screen for new-onset cognitive problems. For adults (18+ years): more comprehensive assessment for anyone who tests positive on initial cognitive screening or demonstrates significant cognitive decline, especially if there are concerns about comorbidities or the individual is applying for disability due to cognitive impairment. For children (<18 years): neuropsychological evaluation for any unexplained change in school functioning (academic or behavioral). Remedial interventions/accommodations for adults and children to improve functioning at home, work, or school.

Rapid cognitive screening in multiple sclerosis accomplished by the Free Recall and Recognition Test

2007 ◽  
Vol 13 (2) ◽  
pp. 272-274 ◽  
Author(s):  
Im Claesson ◽  
C Ytterberg ◽  
S Johansson ◽  
O Almkvist ◽  
L Von Koch
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Free Recall ◽  
Disease Severity ◽  
Recognition Test ◽  
Screening Tool ◽  
Cognitive Tests ◽  
Cognitive Screening ◽  
Severity Rating ◽  
Serial Addition

This study sought to investigate the feasibility of the Free Recall and Recognition Test (FRRT) as a practical screening tool for cognitive impairment in multiple sclerosis (MS). Persons with MS (n =227) were consecutively recruited and assessed with four cognitive tests; FRRT, Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and the Mini-Mental State Examination (MMSE). Disease severity was assessed by the Expanded Disability Status Scale (EDSS). The FRRT, which was completed by 99% of the cohort in approximately 5 minutes per assessment, correlated significantly with the other cognitive tests, as well as with the disease severity rating. A cut-off of 4 for the FRRT recall rendered 90% sensitivity and 25% specificity, and a cut-off of 4.2 for the FRRT recognition resulted in 70% sensitivity and 51% specificity. We conclude that the FRRT proved feasible as a practical screening tool for cognitive impairment in MS within a clinical setting. Multiple Sclerosis 2007; 13: 272–274. http://msj.sagepub.com

Is your vision blurry? A systematic review of home-based visual acuity for telemedicine

2020 ◽  
pp. 1357633X2097039
Author(s):  
Anindya Samanta ◽  
Shielah Mauntana ◽  
Zahra Barsi ◽  
Bina Yarlagadda ◽  
Patricia C Nelson
Keyword(s):  
Visual Acuity ◽  
Screening Tool ◽  
Reference Standard ◽  
Retest Reliability ◽  
Home Based ◽  
Home Testing ◽  
The World ◽  
Minimum Angle ◽  
Measured Distance ◽  
Test Retest Reliability

Introduction Visual acuity (VA) testing is a vital screening tool for the assessment of ocular function. The coronavirus 2019 pandemic has caused an immediate need for synchronous telemedicine in all specialties, including ophthalmology. While a plethora of mobile VA applications exist, there is no consensus as to what technology can accurately and reproducibly measure a patient’s vision at home. Methods A systematic literature search was performed in April 2020 using PubMed, Embase and Medline, identifying English publications from 2010 to 2020 on remote VA tests: 4338 articles were identified and 14 were ultimately included in the review. Results Of those 14, the highest quality studies, best reproducibility and correlation with in-clinic acuities measured were found using the Peek Acuity application. The studies included patients throughout the world aged 3–97, with and without correction, with known ocular pathology. The Peek Acuity studies measured distance vision on a Samsung Galaxy S3 with a mean difference of 0.055 Logarithm of the Minimum Angle of Resolution (LogMAR) for home testing compared with the Early Treatment Diabetic Retinopathy Study (ETDRS). Test–retest variability was ±0.029 LogMAR for 95% confidence interval limits. Discussion There can be one or more lines of variability in vision testing in a clinical setting using reference standard ETDRS and clinical standard Snellen charts. Test–retest reliability is not perfect even on standard clinical charts (variation up to 0.48 LogMAR). Of the technologies reviewed, Peek Acuity home testing had the greatest correlation with ETDRS clinical vision and high test–retest reliability. Peek Acuity performed no worse than Snellen and ETDRS charts.

The Colorado Cognitive Assessment (CoCA): Development of an Advanced Neuropsychological Screening Tool

2019 ◽  
Author(s):  
Ashita S. Gurnani ◽  
Shayne S.-H. Lin ◽  
Brandon E Gavett
Keyword(s):  
Construct Validity ◽  
Psychometric Properties ◽  
Cognitive Assessment ◽  
Screening Tool ◽  
Depression Scale ◽  
Internal Consistency Reliability ◽  
Screening Tests ◽  
Cognitive Screening ◽  
Analysis Model ◽  
Factor Analysis Model

Objective: The Colorado Cognitive Assessment (CoCA) was designed to improve upon existing screening tests in a number of ways, including enhanced psychometric properties and minimization of bias across diverse groups. This paper describes the initial validation study of the CoCA, which seeks to describe the test; demonstrate its construct validity; measurement invariance to age, education, sex, and mood symptoms; and compare it to the Montreal Cognitive Assessment (MoCA). Method: Participants included 151 older adults (MAge = 71.21, SD = 8.05) who were administered the CoCA, MoCA, Judgment test from the Neuropsychological Assessment Battery (NAB), 15-item version of the Geriatric Depression Scale (GDS-15), and 10-item version of the Geriatric Anxiety Scale (GAS-10). Results: A single factor confirmatory factor analysis model of the CoCA fit the data well, CFI = 0.955; RMSEA = 0.033. The CoCA’s internal consistency reliability was .84, compared to .74 for the MoCA. The CoCA had stronger disattenuated correlations with the MoCA (r = .79) and NAB Judgment (r = .47) and weaker correlations with the GDS-15 (r = -.36) and GAS-10 (r = -.15), supporting its construct validity. Finally, when analyzed using multiple indicators, multiple causes (MIMIC) modeling, the CoCA showed no evidence of measurement non-invariance, unlike the MoCA. Conclusions: These results provide initial evidence to suggest that the CoCA is a valid cognitive screening tool that offers numerous advantages over the MoCA, including superior psychometric properties and measurement non-invariance. Additional validation and normative studies are warranted.

Sign in / Sign up

Export Citation Format

Share Document